S-100B Protein and its diagnostic value in melanoma
Abstract
We evaluated serum S-100B protein in 45 patients with melanoma and in 40 healthy donors as a control group. Results revealed elevation of S-100В in cases with primary tumors and cases with recurrent disease. Test sensitivity was 63%, specificity – 72,5%, accuracy – 67,4%. S-100B is primary diagnostic marker that may predict disease progression but further studies are needed.
About the Authors
L. Kh. Mukhamatgaleeva
Kazan State Medical Academy;
Maryi El Cancer Center
Russian Federation
Russian Federation
Ioshkar-Ola
Z. A. Afanaseva
Kazan State Medical Academy;
Maryi El Cancer Center
Russian Federation
Russian Federation
Ioshkar-Ola
G. A. Usmanova
Clinical oncology center
Russian Federation
Russian Federation
Kazan
References
1. Демидов Л.В., Утяшев И.А. Хирургическое лечение меланомы кожи. Практическая онкология. 2012, т. 13, № 2, с. 125-134.
2. Vereecken P., Cornelis F., Van Baren N., Vandersleyen V., Baurain J.F. A synopsis of serum biomarkers in cutaneus melanoma patients. Hindawi Publishing Corporation Dermatology Research and Practice. 2012, v. 7.
3. Liu S., Kirschmeier P., Simon J., Seidel-Dugan C., Puhlmann M. Prognostic and predictive molecular markers in cutaneous malignant melanoma: the first step toward personalized medicine. Current Pharmacogenomics and Personalized Medicine. 2008, v. 6, p. 272-294.
4. Slominski A. Neuroendocrine activity of the melanocyte. Exp. Dermatol. 2009, v. 18, No. 9, p. 760-763.
5. Сергеева Н.С., Маршутина Н.В. Общие представления о серологических биомаркерах и их месте в онкологии. Практическая онкология. 2011, т. 12, № 4, с. 147-154.
6. Снеговой А.В., Манзюк Л.В. Значение биомаркеров для определения тактики лечения и прогноза злокачественных опухолей. Практическая онкология. 2011, т. 12, №4, с. 166-170.
7. Faries M.B., Gupta R.K., Ye Y. et al. A comparison of 3 tumor markers (MIA, TA90IC, S-100B) in stag III melanoma patients. Cancer Invest. 2007, v. 25, No. 5, p. 285-293.
8. Сергеева Н.С., Лазутина Т.Н., Мишунина М.П. и соавт. Определение белка S-100 как серологического опухоль-ассоциированного маркера при меланоме. Российский онкологический журнал. 2008, № 2, с. 19-22.
9. Abraha H.D., Nobel P.L., Nicolaides K.H., Sherwood R.A. Maternal serum S100 protein in normal and Down Syndrome pregnancies. Prenatal Diagnosis. 1999, v. 19, p. 334-336.
10. Smit L.H.M., Nieweg O.E., Mooi W.J., Bonfrer J.M.G., Haanen J.B.A.G., Kroon B.B.R., De Gast G.C. Value of serum S-100B for prediction of distant relapse and survival in stage III B/C melanoma. Anticancer Research. 2008, v. 28, p. 2297-2302.
11. Maelandsmo G.M., Florenes V.A., Mellingsaeter T., HovigE., Kerbel R.S., Fodstad O. Differential expression patterns of S100A2, S100A4 and S100A6 during progression of human malignant melanoma. Int. J. Cancer (Pred. Oncol.). 1997, v. 74, p. 464-469.
12. Miwa N., Uebi T., Kawamura S. S100-annexin complexes – biology of conditional association. FEBS Journal. 2008, v. 275, p. 4945-4955.
13. Banfalvi T., Boldizsar M., Gergye M., Gilde K., Kremmer T., Otto S. Comparison of prognostic significance of serum 5-S-Cysteinydopa, LDH and S-100B protein in stage III–IV malignant melanoma. Pathology Oncology Research. 2002, v. 8, No. 3.
14. Fritz G., Botelho H.M., Morozova-Roche L.A., Gomes C.M. Natural and amyloid self-assembly of S100 proteins: structural basis of functional diversity. FEBS Journal. 2010, v. 227, No. 22, p. 4578-4590.
15. Bottoni U., Izzo P., Richetta A., Mannooranparampil T.J., Devirgiliis V., GiudiceM.D., RealeM.G., Frati L., Calvieri S. S100 serum level: a tumour marker for metastatic melanoma. Melanoma Research. 2003, v. 13, p. 427-429.
16. Tarhini A.A., Stuckert J., Lee S., Sander C., Kirkwood J.M. Prognostic significance of serum S100 protein in high-risk surgically resected melanoma patients participating in Intergroup Trial ECOG 1694. J. Clin. Oncol. 2009, v. 27, No. 1, p. 38-44.
17. Balch C.M., Gershenwald J.E., Soong S.J., Thompson J.F., Atkins M.B. et al. Final version of 2009 AJCC melanoma staging and classification. J. of Clin. Oncol. 2009, v. 27, No. 36, p. 6199-6206.
18. Bolandera A., Agnarsdottir M., Wageniusa G., Strömberg S., Ponten F., Ekmana S., Brattström D., Larsson A., Einarssone R., Ullenhaga G., Hesseliusa P., Berggvista M. Serological and immunohistochemical analysis of S100 and new derivatives as markers for prognosis in patients with malignant melanoma. Melanoma Research. 2008, v. 18, p. 412-419.
19. Palmer S.R., Erickson L.A., Ichetovkin I., Knauer D.J., Markovic S.N. Circulating serologic and molecular biomarkers in malignant melanoma. Mayo Clin. Proc. 2011, v. 86, No. 10, p. 981-990.
20. Guo H.B., Stoffel-Wagner B., Bierwirth T. et al. Clinical significance of serum S-100 in metastatic malignant melanoma. Eur. J. Cancer. 1995, v. 11, p. 1898-1902.
21. Von Schoultz E., Hansson L.O., Djureen E., Hansson J., Karnell R., Nilsson B. et al. Prognostic value of serum analysis of S-100B protein in malignant melanoma. Melanoma Res. 1996, v. 6, p. 133-137.
Review
For citations:
Mukhamatgaleeva L.Kh., Afanaseva Z.A., Usmanova G.A. S-100B Protein and its diagnostic value in melanoma. Bone and soft tissue sarcomas, tumors of the skin. 2016;(1):65-69. (In Russ.)
Views:
89
Email this article 
